Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,869,426
  • Shares Outstanding, K 91,579
  • Annual Sales, $ 451,240 K
  • Annual Income, $ 21,110 K
  • 60-Month Beta 1.22
  • Price/Sales 19.03
  • Price/Cash Flow 187.01
  • Price/Book 17.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 0.66
  • Number of Estimates 10
  • High Estimate 0.79
  • Low Estimate 0.42
  • Prior Year 0.52
  • Growth Rate Est. (year over year) +26.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.68 +13.11%
on 10/08/19
102.50 -6.56%
on 09/20/19
-5.34 (-5.28%)
since 09/18/19
3-Month
83.83 +14.25%
on 07/24/19
102.50 -6.56%
on 09/20/19
+7.27 (+8.21%)
since 07/18/19
52-Week
64.72 +47.99%
on 12/12/18
116.48 -17.77%
on 10/19/18
-18.80 (-16.41%)
since 10/18/18

Most Recent Stories

More News
Bet on Top-Notch Sector ETFs & Stocks to Sparkle Q4

Investors could be well served by ETFs and stocks from sectors that house top-ranked industries.

NRG : 40.15 (+1.01%)
LDOS : 81.62 (-0.11%)
MTZ : 67.85 (+0.43%)
ITA : 215.92 (-2.55%)
ITB : 45.27 (+0.71%)
XLU : 63.82 (+0.33%)
XLV : 91.76 (-0.37%)
NBIX : 95.78 (-1.10%)
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, November 4, 2019. Neurocrine will then host a conference...

NBIX : 95.78 (-1.10%)
Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ZTS : 128.12 (-0.27%)
JAZZ : 119.65 (-1.22%)
UTHR : 82.14 (+0.58%)
NBIX : 95.78 (-1.10%)
CTLT or NBIX: Which Is the Better Value Stock Right Now?

CTLT vs. NBIX: Which Stock Is the Better Value Option?

CTLT : 48.63 (-2.21%)
NBIX : 95.78 (-1.10%)
Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg dose of INGREZZA® (valbenazine) capsules in reducing abnormal...

NBIX : 95.78 (-1.10%)
Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data analyses evaluating the long-term effects of once-daily 40 mg INGREZZA® (valbenazine) in adults with tardive dyskinesia...

NBIX : 95.78 (-1.10%)
Neurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that David W. Boyer has joined the company's executive management team as Chief Corporate Affairs Officer. Boyer joins Neurocrine Biosciences...

NBIX : 95.78 (-1.10%)
Neurocrine Biosc Up 14.4% Since SmarTrend Uptrend Call (NBIX)

SmarTrend identified an Uptrend for Neurocrine Biosc (NASDAQ:NBIX) on May 31st, 2019 at $83.76. In approximately 4 months, Neurocrine Biosc has returned 14.39% as of today's recent price of $95.81.

NBIX : 95.78 (-1.10%)
Neurocrine Biosc Has Returned 20.6% Since SmarTrend Recommendation (NBIX)

SmarTrend identified an Uptrend for Neurocrine Biosc (NASDAQ:NBIX) on May 31st, 2019 at $83.76. In approximately 4 months, Neurocrine Biosc has returned 20.61% as of today's recent price of $101.02.

NBIX : 95.78 (-1.10%)
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

NBIX : 95.78 (-1.10%)
GNCA : 2.61 (-1.14%)
REPH : 12.18 (+0.50%)
ZTS : 128.12 (-0.27%)
CPRX : 5.24 (-1.04%)
FLXN : 14.24 (-1.25%)
VRCA : 14.65 (-1.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade NBIX with:

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

2nd Resistance Point 103.41
1st Resistance Point 99.59
Last Price 95.78
1st Support Level 92.78
2nd Support Level 89.79

See More

52-Week High 116.48
Fibonacci 61.8% 96.71
Last Price 95.78
Fibonacci 50% 90.60
Fibonacci 38.2% 84.49
52-Week Low 64.72

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar